11. Network effect estimates and ranking statistics for cerebral palsy.

Acetaminophen Mean SUCRA, 0.76; median rank, 1 (95% CrI, 1‐3)
0.38 ( 0.01, 6.97)	Indomethacin Mean SUCRA, 0.39; median rank, 2 (95% CrI, 1‐3)
0.36 ( 0.01, 6.31)	0.97 ( 0.44, 2.11)	Placebo Mean SUCRA, 0.35; median rank, 2 (95% CrI, 1‐3)

The unlabeled data in the boxes are risk ratios (RRs) and 95% credible intervals (CrIs). A RR >1 suggests that the upper left treatment is associated with a higher risk of having the outcome of interest vs the corresponding lower right treatment and the opposite is true for an RR <1. SUCRA, surface under the cumulative ranking curve